Emergency use is defined as the use of an investigational drug or biological product with a human subject in a life-threatening situation in which no standard acceptable treatment is available and in which there is not sufficient time to obtain institutional review board (IRB) approval [21 CFR 56.102(d)].
The emergency use provision in the Food and Drug Administration (FDA) regulations [21 CFR 56.104(c)] is an exemption from prior IRB review and approval. The exemption, which may not be used unless all of the conditions described in 21 CFR 56.102(d) exist, allows for one emergency use of a test article without prospective IRB review.
FDA regulations require that any subsequent use of the investigational product at the institution have prospective IRB review and approval. The FDA acknowledges, however, that it would be inappropriate to deny emergency treatment to a second individual if the only obstacle is that the IRB has not had sufficient time to convene a meeting to review the issue. [21 CFR 56.102(d) Emergency use means the use of a test article on a human subject in a life-threatening situation in which no standard acceptable treatment is available, and in which there is not sufficient time to obtain IRB approval.]
Life-threatening, for the purposes of section 56.102(d), includes the scope of both life-threatening and severely debilitating:
Life-threatening means diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions with potentially fatal outcomes, where the end point of clinical trial analysis is survival. The criteria for life-threatening do not require the condition to be immediately life-threatening or to immediately result in death. Rather, the subjects must be in a life-threatening situation requiring intervention before review at a convened meeting of the IRB is feasible.
Severely debilitating means diseases or conditions that cause major irreversible morbidity. Examples of severely debilitating conditions include blindness, loss of arm, leg, hand or foot, loss of hearing, paralysis or stroke.
Institutional procedures may require that the IRB be notified prior to such use, however, this notification should not be construed as an IRB approval. The IRB uses this notification to initiate tracking to ensure that the investigator files a report within the five day time frame required by 21 CFR 56.104(c).
The FDA regulations do not provide for expedited IRB approval in emergency situations. Therefore, "interim," "compassionate," "temporary" or other terms for an expedited approval process are not authorized. An IRB must either convene and give full board approval of the emergency use or, if the conditions of 21 CFR 56.102(d) are met and it is not possible to convene a quorum within the time available, the use may proceed without any IRB approval.
Some manufacturers will agree to allow the use of the test article, but their policy requires an IRB approval letter before the test article will be shipped. If it is not possible to convene a quorum of the IRB within the time available, some IRBs have sent a written statement to the sponsor that the board is aware of the proposed use and considers the use to meet the requirements of 21 CFR 56.104(c). Although, this is not an IRB approval, the acknowledgment letter has been acceptable to manufacturers and has allowed the shipment to proceed.